Overview

This trial is active, not recruiting.

Condition cervical intraepithelial neoplasia
Treatment gx-188e
Phase phase 2
Targets FLT-3, HPV-16, HPV-18
Sponsor Genexine, Inc.
Start date May 2014
End date August 2016
Trial size 72 participants
Trial identifier NCT02139267, GX-188E_CIN3_P2

Summary

The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
gx-188e DNA therapeutic vaccine
DNA vaccine administered via IM route using TDS-IM electroporation device
(Experimental)
4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
gx-188e DNA therapeutic vaccine
DNA vaccine administered via IM route using TDS-IM electroporation device

Primary Outcomes

Measure
The Rate of Participants with Histopathological Regression of Cervical Lesions to CIN1 or Less
time frame: 20 weeks

Secondary Outcomes

Measure
The Rate of Participants Whose Result Inverted Negative in HPV DNA test
time frame: 20 weeks
The rate of HPV E6, E7-specific ELISPOT responder defined in the protocol
time frame: 20 weeks
Cytological Changes of the Cervical Lesions
time frame: 20 weeks
The Rate of Adverse Events and the Related Features after Administration of Investigational Product
time frame: 20 weeks
The Rate of Solicited Adverse Events and the Related Features
time frame: 20 weeks
Data in Physical examination, Vital signs, Electrocardiography, Clinical Laboratory Test Results Related to Investigational Product
time frame: 20 weeks
Mean Value of Visual Analogue Scale on Pain Intensity
time frame: 20 weeks
Flt-3L Serum Concentration
time frame: 20 weeks

Eligibility Criteria

Female participants from 19 years up to 50 years old.

Inclusion Criteria: 1. Voluntarily signed informed consent form after receiving education about this study and the investigational product. 2. Female aged between 19 and 50 years 3. Positive test results for HPV Type 16 and/or Type 18 4. Histopathologically-confirmed Cervical Intraepithelial Neoplasia 3 5. Entire cervical area including entire squamocolumnar junction is visualized through colposcopy 6. Eligible based on screening test results. 7. Promised not to get pregnant throughout the study Exclusion Criteria: 1. Suspected Adenocarcinoma in situ 2. Malignant cancer more than Stage I 3. Pregnancy or breastfeeding 4. Participation in clinical trials within 30 days of the screening visit 5. Administration of immunosuppressant or immunomodulator within 6 months prior to the enrolment 6. Administered with systemic steroid(as a standard with Prednisolone, more than 20mg/day for every 14 days or more) within 3 months of Day 1(including ointment, eye drops, inhalated or nasal, intra-ligamental or intra-articular injection, but not applicable if injected every other day 7. Administered any blood products within 3 months prior to the screening visit 8. Administered any vaccine within 4 weeks prior to the screening visit(ex. Hepatitis A, Hepatitis B, Influenza, Td etc.) 9. Positive serum test results for hepatitis C virus, hepatitis B virus surface antigen(HBsAg) or HIV 10. Severe hepatopathy which is Class C according to Child-Pough's classification 11. Severe renal dysfunction where the creatinine clearance(CLcr) is lower than 30ml/min 12. CPK test results more than 2.5 times the upper limit of normal 13. Predisposed to inflammatory reaction due to use of medical devices such as electroporation within 30 days of screening visit 14. History of severe adverse drug events or severe allergic diseases 15. History of epilepsy or convulsion within 2 years prior to the screening visit 16. At the discretion of the investigator, the skin condition covering deltoid muscles, within 2cm of the intended sites of injection, is not suitable for injection due to infection, ulcer, edema, tattoo, scar, injury etc. 17. The thickness of skin fold covering deltoid muscles, intended injection sites, > 40mm 18. Any orthopedic artificial implant around the intended sites of electroporation (deltoid muscles) 19. Sinus bradycardia whose resting heart rate < 50 beats/min 20. Pre-excitation syndrome such as Wolff-Parkinson-White syndrome 21. Abnormal electrocardiography(ECG) including arrhythmia 22. Artificial implants or metallic implants 23. Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study

Additional Information

Official title A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)
Principal investigator Park Jong-Sup, M.D.
Description Subjects who are eligible for this study are allocated to one of the two treatment groups of GX-188E. All Subject received GX-188E intramuscularly using the electroporator(EP) on alternating deltoid muscles which will be performed totally three times during the study period.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Genexine, Inc..